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Aim: To depict heterogeneous clinical features of atypical Guillain-Barré syndrome (GBS) variants overlapping between 
different GBS types and subtypes. Methods: Retrospective analysis of data comprising neurological features, cerebrospinal 
fl uid (CSF) analysis, ganglioside antibody testing results, electromyography (EMG) fi ndings, brain and spinal magnetic 
resonance imaging (MRI) in all pediatric patients with GBS treated during a 10-year period at a tertiary center. Results: 
Twenty-three children were treated for GBS during the study period. Atypical variants were found in fi ve patients and 
included bifacial and severe pharyngocervicobrachial weakness of descending type, sixth nerve lesion accompanied with 
lower extremity paresthesias, sensory atactic neuropathy and facial nerve lesion, acute ptosis with mydriasis and incomplete 
Miller Fisher syndrome, and bilateral facial nerve paresis (one case each). Initial CSF analysis revealed mostly normal protein 
level in atypical variants. MRI evaluation was normal in all atypical variants except for enhancement of the cervical nerve 
roots in a patient with pharyngocervicobrachial subtype. EMG performed in the fi rst two weeks showed prolonged distal 
latency and proximal conduction block in 3/5 patients, in elicitable nerves and axonal loss on upper extremities in a patient 
with pharyngocervicobrachial subtype, and absent F-waves and neural potentials in 3/5 patients. Slight decrease of motor 
conduction velocity was present in 2/5 patients in distal nerve segments. Antiganglioside antibodies were positive in 4/5 patients. 
Conclusion: Clinical manifestations of GBS are very variable, whereas atypical variants/overlaps are not so uncommon. This 
study supports the proposed hypothesis of continuous spectrum of GBS requiring reconsideration of the existing diagnostic 
criteria for classic GBS in pediatric population supported by recently proposed (published) diagnostic guidelines.
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INTRODUCTION
Guillain-Barré syndrome (GBS) is the most com-
mon acute peripheral neuropathy in children. Still, its 
pathogenesis is not yet completely understood, with a 
broad spectrum of signs and symptoms, nadir within 
four weeks from onset, and recovery in a few weeks 
(1,2). Th e incidence of GBS in children varies between 
0.4 and 1.3/100,000 per year, being more common 
in children aged 10-18 years (1-5). GBS is an im-
mune-mediated postinfectious heterogeneous disor-
der which encompasses diff erent typical (classic) and 
atypical, localized and incomplete forms indicating a 
spectrum of disease (6-9). Classic GBS  includes acute 
axonal motor neuropathy (AMAN), acute axonal mo-
tor and sensory neuropathy (AMSAN) if additionally 
sensory fi bers are aff ected, and acute infl ammatory 
demyelinating polyneuropathy (AIDP). Classic vari-
ants are characterized by certain clinical features such 
as history of antecedent infection (respiratory or gas-
trointestinal), monophasic disease course and rapidly 
progressive symmetric, bilateral limb weakness with 
arefl exia or hyporefl exia accompanied with a typical 
fi nding of cerebrospinal fl uid (CSF) albumin cytolog-
ic dissociation (raised protein concentration, normal 
cell count, although normal protein content does not 
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exclude GBS), positive antiganglioside antibodies, and 
neurophysiological evidence for axonal and/or demy-
elinating neuropathy. All mentioned above support 
the diagnosis of GBS, but are not specifi c, therefore 
should not be relied upon, especially at the inception 
of symptoms (7,10-12). Electrophysiologic abnormal-
ities are oft en delayed, thus repeated neurophysiologic 
testing is sometimes needed. As the fi rst electrophysi-
ologic abnormalities occur, i.e. prolongation of F wave 
and distal latency, repeated testing is not mandatory 
(4,13). Th erefore, diagnosis of GBS is initially depen-
dent on unspecifi c clinical manifestations including 
pain, numbness, paresthesias, and ataxia (14). In-
volvement of respiratory muscles (respiratory failure 
in up to 20%) or cranial nerves (in 30%-50% of cases) 
may develop, as well as hyperrefl exia or normal re-
fl exes in 10% of cases (4,7,14). Unusual presentations 
and atypical variants lead to misdiagnosis and delayed 
management, thus GBS remains a challenge for prac-
titioners (15). Diff erential diagnosis is rather broad. 
Certain mimics of acute fl accid paraparesis compli-
cate diagnosis, especially of atypical/incomplete GBS 
variants due to similarity to the overlapping syndrome 
(7,8,16). Th erefore, neuroimaging plays an important 
role in diagnostic pathway by excluding other causes 
of acute neuromuscular paralysis (7). Even though 
the outcome is generally favorable with self-limitating 
course of the disease, autonomic system could be af-
fected (cardiac arrythmias, respiratory insuffi  ciency) 
leading to lethal outcome in 5%-13% of pediatric cas-
es (17). Atypical variants are more likely to have rap-
id deterioration with increasing severity of disability 
scores (mean and at nadir), cranial nerve involvement, 
dysautonomia (Erasmus GBS Respiratory insuffi  cien-
cy score, urinary incontinence) with relative preserva-
tion of muscle strength in the extremities (6,7,18-21). 
Furthermore, chronic demyelinating polyneuropathy 
(CIDP) may develop in 3%-5% of GBS patients. Th ere-
fore, early diagnosis and management is important for 
timely monitoring of complications and rational ther-
apeutic approach including plasma exchange (PE), 
intravenous immunoglobulins (IVIG), and supportive 
measures (physiotherapy, analgesia due to neuropath-
ic pain) (4,7,10,12,21). We conducted this study with 
the purpose to present clinical pattern and outcome in 
pediatric patients with GBS and atypical forms, treat-
ed in a Croatian tertiary center. 
PATIENTS AND METHODS
Th is was a retrospective case-series single center study. 
Medical records of all patients with GBS treated from 
2005 to 2014 in a pediatric tertiary center (Department 
of Pediatrics, Zagreb University Hospital Centre) were 
evaluated. Patients included in the study met diagnostic 
criteria for GBS (7). Patients with positive medical his-
tory of previous neurological signs and symptoms and 
abnormal psychomotor development were excluded 
from the study. Pediatric neurologist reviewed medical 
fi les of the patients. Th e following data were extracted 
from medical fi les: age, gender, neurological features, 
CSF fi ndings, ganglioside antibody studies, electromy-
ography (EMG), brain and spinal magnetic resonance 
imaging (MRI). Serum samples were analyzed for pos-
sible causative bacterial (Campylobacter jejuni, Borrel-
ia burgdorferi and Mycoplasma pneumoniae) or viral 
etiology (Epstein-Barr virus (EBV), cytomegalovirus 
(CMV)). Th e GBS classic subtypes or variants accord-
ing to electroneurographic studies were documented as 
AMAN and AIDP. EMG was performed by expert pedi-
atric neurologist with concentric needles; motor fi bers 
were studied by needle recording and surface electrode 
stimulation, while sensory fi bers were studied by or-
thodromic recording from wrist and ankle. Compound 
muscle action potential amplitude (CMAP), motor 
nerve conduction velocity (MNCV), neural potential 
amplitude, sensory nerve conduction velocity (SNCV), 
F-wave latency, distal latency (DL) and proximal to 
distal CMAP (P/D) ratio were measured. Recruitment 
pattern and spontaneous activity were recorded by nee-
dle electrode in small hand muscles and extensor brevis 
muscles. Motor conduction studies were polysegmen-
tally determined and were performed on peroneal, ulnar 
and median nerves. In each patient, three to four nerves 
were examined. Normal values and electrophysiologic 
criteria for demyelination and axonal degeneration were 
referred to accepted and proposed ones (14). Children’s 
surface body temperature was between 36.9 °C and 37.0 
°C axillary. Serum IgG and IgM anti-ganglioside anti-
bodies (anti-GM1, anti-GD1a, anti-GD1b, anti-GQ1b) 
were measured by enzyme-linked immunosorbent as-
say (ELISA) (Gan-gliocombi, Bühlmann Laboratories 
AG, Basel, Switzerland). GBS disability scale was used 
to assess the severity of disease (18).
RESULTS
Overall, 23 patients with GBS were treated during 
the ten-year period (Table 1), 18 of them with typi-
cal GBS (12 male; age 2 to 15 years). Atypical variants 
were found in 5 patients (4 male; age 2 to 10 years) 
and included bifacial and severe pharyngocervicobra-
chial weakness of descending type, sixth nerve lesion 
accompanied with lower extremity paresthesias, sen-
sory atactic neuropathy accompanied by facial nerve 
lesion, acute ptosis with mydriasis and incomplete 
Miller Fisher syndrome, and bilateral paresis of facial 
nerve (one case each). Detailed patient characteristics 
and evaluation is shown in Table 1. Representative 
cases of atypical variants are presented below.  
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Case 1
A 9-year-old boy presented with weakness of upper 
extremities and swallowing. Bilateral facial nerve 
and unilateral abducent nerve lesion, plegia of upper 
limbs, hyperrefl exia, neck weakness and hyperhidrosis 
were observed. On day 8 of disease, the patient devel-
oped lower limb paresis and weak cough refl ex. GBS 
disability score was categorized as bedridden or chair 
bound (modifi ed Rankin score 4). His condition dete-
riorated during the third week of disease. Lower limbs 
recovered fi rst aft er four weeks.
Case 2
A 6-year-old boy presented with right eye pain and 
diplopia. Unilateral lesion of abducent nerve, left  leg 
weakness, bilateral hyperrefl exia and paresthesias with 
positive plantar extensor response on the left  foot were 
observed. 
Case 3
A 10-year-old boy presented with progressive gener-
alized ataxia, dizziness and unstable gait. Limb par-
esthesias and mild bilateral facial nerve lesion, distal 
limb hypesthesia and decreased pain sensitivity were 
observed. He was unstable on Romberg test as well. 
GBS disability score was 4. 
Case 4
A 5-year-old boy was admitted due to sudden onset of 
ophthalmoparesis accompanied by mydriasis and low 
intensity headache. Anisocoria, ptosis and nystagmus on 
the right eye were noticed. GBS disability score was 2. 
Case 5
A 2-year-old girl presented with bilateral intermittent 
ptosis on both eyes, asymmetric grimacing, and de-
creased tendon refl exes on both upper and lower ex-
tremities. GBS disability score was 1.
Table 1. Demographics, clinical profi le, evaluation and treatment of studied patients
Patients treated 
for GBS (N=23)
Typical („classic“) GBS (N=18)
Atypical GBS/GBS variants (“chameleons”) (N=5)
PCB /GBS – LS MFS - IF SAN/MFS - IF MFS - IF GBS - LS
Age (years) Median 6.5 (range 2 -15) 9 6 10 5 2
Gender 12 male, 6 female Male Male Male Male Female
Antecedent 
infection
Respiratory 6/18- 2 M. pneumoniae, 1 
VZV IgM positive in CSF gastrointe-
stinal 3/18 - 1 Campylobacter spp.
Respiratory (mild rhinitis 7 
days before); nontypable 
N.meningitidis in tracheal 
aspirate in week 3
Respiratory Respiratory Respiratory
Respiratory infection 
treated with amoxicillin 




Ascending type 15/18; cranial nerve 
involvement 2/18
Upper extremities with 
generalization in second week
Asymmetric No
In addition to 
anisocoria andptosis




Areflexia 10/18; hyporeflexia 3/18; 






Nadir (days) Median 7 (range 3-28) 6 2 10 8 10
Protein content  
CSF analysis 
(g/L)
Median 0.59 (range 0.35-1.98)
Initial normal; Repeated 3rd 
week 0.39, next 2.2
Normal Normal Normal 0.39
EMG findings
AIDP 11/18; AMAN 4/18; both axonal 
and demyelinating (equivocal) 2/18 
AMAN; inelicitable nerves 
(musculocutaneous nerve) 
or very low proxymal CMAP 
in ulnar nerve and median 
nerve (0.2-0.4 mV) on upper 
extremities, absent F waves









low distal CMAP; 
F- wave latency; 
prolonged DL; 
equivocal




Positive in 10/12 (8 had positive anti-
GM1; 5 had multiple antibodies, 4 
had anti-GD1b, anti-GQ1b IgG). Highly 
specific MFS antibodies were negative 
in all patients




Brain and spinal 
cord MRI
-
Initial normal; repeated 4 
weeks after disease showed 
enhancement of cervical nerve 
roots 
Normal Normal Normal Normal
Therapy
IVIG 10/18; IVIG and steroids 4/18; 
steroids exclusively 1/18, spontaneous 
recovery 1/18, NA 2/18












AIDP = acute infl ammatory demyelinating polyneuropathy; AMAN = acute axonal motor neuropathy; anti-GM1/anti-GD1a/anti-GD1b/
anti-GQ1b = antiganglioside antibodies; CMAP = compound muscle action potential amplitude; CSF = cerebrospinal fl uid; DL = distal laten-
cy; EMG = electromyography; GBS = Guillain-Barré syndrome; IF = incomplete form; IVIG = intravenous immunoglobulin; LS = localized 
subtype; MFS = Miller Fisher syndrome; MNCV = motor nerve conduction velocity; MRI = magnetic reasonance imaging; PCB = pharyngo-
cervicobrachial; PE = plasma exchange; SAN = sensory ataxic neuropathy; SNCV = sensory nerve conduction velocity; SNAP = sensory nerv 
action potential; VZV = varicella zoster virus
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DISCUSSION
We observed signifi cant clinical variability and sero-
logic heterogeneity of GBS and its atypical variants, 
which supported the proposed hypothesis of contin-
uous spectrum of GBS and reconsideration of the ex-
isting diagnostic criteria for classic GBS in pediatric 
population (7,9,13). Literature data on atypical GBS in 
children are scarce. Our study has demonstrated that 
atypical variants are not uncommon as we thought, 
similar to a recent small study (22). Our cohort with 
typical GBS resembled other populations with Cau-
casian predominance (Europe, United States, Iran, 
Japan), showing male predominance and AIDP oc-
ccurence as the most common neurophysiologic pre-
sentation (17,19,23). Antecedent infection was docu-
mented in all patients with atypical variants and half 
of patients with typical GBS, whereas in the literature 
it rates up to 60%-70% (4,9,24).Th e majority of infec-
tions remained etiologically unproven. GBS is preced-
ed by Campylobacter (most frequently), M. pneumoni-
ae, CMV, EBV, Zika or infl uenza virus infection, and 
recently SARS-Cov-2 infection (13,25-28). Although 
GBS has been reported as a postimmunization event, 
vaccination as a provocative factor in our patients 
was excluded. GBS following previous immunization 
(rabies, H1N1 vaccine) is rare (1.6 cases per 106 vac-
cinations) and probably it is temporally coincidental 
rather than causative (13,29-31). In one of our study 
patients, Neisseria was isolated from the upper respi-
ratory tract specimen. Currently, there is insuffi  cient 
data to confi rm a link between GBS and non-typable 
Neisseria meningitidis carrier state (6). Recently, a 
rare case of MFS aft er Neisseria meningitidis has been 
reported (32). Nadir is reported to be reached at one 
week, as we also found in our survey, similar in atypi-
cal and typical GBS variants (33).
Antiganglioside antibodies become positive early in 
the course of disease and are found in around one-
third of GBS patients (34). In our survey, around half 
of the patients with typical GBS and atypical variants 
had positive antiganglioside antibodies (most com-
monly anti-GM1). Several types of antibodies are 
more frequently observed in some GBS variants (13). 
Up to half of the patients with pharyngocervicobra-
chial GBS subtype (PCB) have positive IgG anti-GT1a 
antibodies which oft en cross-react with GQ1b, where-
as patients with Miller Fisher syndrome (MFS) carry 
mostly IgG anti-GQ1b antibodies which cross-react 
with GT1a (7). Serologic heterogeneity suggests con-
tinuous spectrum of GBS and shows more pathoge-
netic than clinical notability in the evaluation of GBS 
patients. Also, antiganglioside antibodies could be in-
volved in a variety of other diseases including other 
neurological diseases (35). CSF fi ndings usually do not 
diff er between typical GBS and its variants, as found in 
our survey (36). CSF analysis is normal in up to 50% of 
patients with GBS during the fi rst week of disease, and 
shows an increased protein level in most cases when 
obtained one week aft er the onset of weakness (1,13). 
Neuroimaging studies are not routinely used. Howev-
er, due to unusual presentation, all of our patients with 
atypical GBS underwent brain MRI scans and were 
normal except for one patient with enhancement of 
the cervical nerve roots, which is not specifi c to GBS 
and occurs in other infl ammatory neuropathies (neu-
roborreliosis) and even in neurodegenerative disor-
ders (33,37,38).
Short-term outcomes were favorable in typical and 
atypical variants, leading to achievement of full recov-
ery in most patients. Nonlethal outcome was found. 
Th e patient described as case 1 showed signs of au-
tonomic dysfunction which may be life-threatening. 
Swallowing diffi  culties, low and nasal voice, neck 
muscle weakness and low blood oxygen might be early 
signs of respiratory insuffi  ciency. In case of dysphagia 
and weak cough, intubation is recommended (4). Pos-
terior reversible encephalopathy syndrome and pria-
pism have been rarely described in adolescents with 
GBS, being more frequent in adults (39). Th e clinical 
course was more severe and prolonged in the patient 
with descending type of PCB. On the contrary, two pa-
tients (age 2 and 5 years) with atypical variant recov-
ered spontaneously due to mild form of disease (GBS 
disability score 1 and 2). Although IVIG and PE have 
been reported as equally eff ective, IVIG is preferred 
due to practical reasons, and thus more frequently 
used in case of the loss of ability to walk unassisted 
(modifi ed Rankin score 4). Corticosteroids are indi-
cated and effi  cient in up to 80% of patients with dis-
ease progression over week 4 toward week 8. Further 
clinical course could be complicated by development 
of CIDP (when detection of neurofascin 155 IgG4 an-
tibodies against paranodal proteins is considerable), 
or by the occurrence of disease fl uctuation/clinical im-
pairments related to treatment two weeks aft er IVIG 
(40,41).
Previous clinical-serologic studies indicate signifi cant 
overlap between GBS and MFS variants within the 
GBS spectrum (7,42). In our study, three patients with 
atypical GBS showed signs of incomplete MFS forms, 
whereas one patient showed overlap with PCB, as re-
ported by other authors (26). PCB may have fulminant 
presentation with tetraplegia and altered conscious-
ness overlapping with brainstem encephalitis or with 
dysphagia and nasal speech with positive anti-GT1a 
antibodies as incomplete PCB form. Th e pattern of 
neuromuscular weakness in patients with botulism 
also resembles one in MFS and PCB, possibly because 
of molecular target carbohydrate residues on gangli-
osides which serve as receptor for botulinum toxin. 
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Th ere is an increasing number of reported overlaps 
between GBS and acute disseminated encephalo-
myelitis, however, not present in our cohort (28,43). 
Despite some study limitations (modest sample size, 
single-center experience, retrospective nature of the 
present study), we believe that our survey contributes 
to the respective literature by showing interesting in-
sights into GBS and its atypical variants in children.
CONCLUSION
Clinical spectrum of GBS variants might be more 
common than previously thought, as they tend to 
be frequently misdiagnosed. Th e diagnosis is based 
on clinical history, examination and investigation of 
evolved clinical/neurological status, which is hetero-
geneous. As the spectrum of GBS presents with highly 
variable, atypical and incomplete clinical manifesta-
tions, the existing diagnostic criteria for classic GBS in 
pediatric population should be reconsidered, as sup-
ported by the recently proposed and published diag-
nostic guidelines. Accurate diagnosis is important for 
rational and timely treatment. 
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Cilj: Prikazati heterogene kliničke značajke inačica atipičnog Guillain-Barréova sindroma (GBS) te preklapanje između 
različitih GBS tipova i podtipova. Metode: Retrospektivna analiza podataka koji uključuju neurološke značajke, analizu 
cerebrospinalne tekućine, rezultate ispitivanja antigangliozidnih protutijela, nalaze elektromiografi je (EMG), magnetsku re-
zonanciju mozga i kralježnice (MRI), svih pedijatrijskih bolesnika liječenih zbog GBS-a u tercijarnom centru u 10-godišnjem 
razdoblju. Rezultati: Liječeno je ukupno 23 djece zbog GBS-a. Atipične varijante pronađene su u pet bolesnika i uključivale 
su bifacijalnu i tešku faringo-cerviko-brahijalnu silaznu slabost, leziju šestog živca popraćenu parestezijama donjih ekstre-
miteta, senzoričku ataktičnu neuropatiju i leziju facijalnog živca, akutnu ptozu s midrijazom i nepotpunim Miller Fisherovim 
sindromom te bilateralnu parezu facijalnog živca (sve po jedan slučaj). Inicijalna analiza cerebrospinalne tekućine pokazala 
je većinom normalnu razinu proteina. Radiološka obrada je bila uredna u svim atipičnim varijantama osim u bolesnika s 
faringo-cerviko-brahijalnom varijantom gdje je nađen pojačan signal u korijenu živaca cervikalne kralježnice. EMG je prva 
dva tjedna bolesti pokazao produljenu distalnu latenciju i proksimalni blok u 3/5 bolesnika, gubitak aksona na gornjim 
ekstremitetima u bolesnika s faringo-cerviko-brahijalnim podtipom te odsutne F-valove i neuronske potencijale u 3/5 bole-
snika. Blago smanjenje brzine provođenja u distalnim segmentima živaca bilo je prisutno u 2/5 bolesnika. Antigangliozidna 
protutijela bila su pozitivna u 4/5 bolesnika. Zaključak: Kliničke manifestacije GBS-a vrlo su varijabilne, a atipične varijante/
preklapanja nisu rijetke. Ovo istraživanje podupire predloženu hipotezu o kontinuiranom spektru GBS-a koja zahtijeva pre-
ispitivanje postojećih dijagnostičkih kriterija za klasični GBS u dječjoj populaciji te uključenje kriterija za varijante GBS-a 
koji su nedavno predloženi i objavljeni.
Ključne riječi: Guillain-Barréov sindrom, polineuropatija, atipične varijante, djeca
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